small-logo
ProfessionalsCapabilitiesInsights & NewsCareersLocations
About UsAlumniOpportunity & InclusionPro BonoCorporate Social Responsibility
Stay Connected:
facebookinstagramlinkedintwitteryoutube
Site Search
  • Professionals (115)
  • Capabilities (44)
  • Experience (111)
  • Insights & News (839)
  • Other Results (36)

Professionals 115 results

Kate L. Price
Kate L. Price
Partner
  • Chicago
Email
+1 312-558-7927
vCard

Partner

  • Chicago
Conor Reidy
Conor Reidy
Partner
  • Chicago
Email
+1 312-558-7542
vCard

Partner

  • Chicago
Anthony Baker
Anthony Baker
Associate
  • Chicago
Email
+1 312-558-8133
vCard

Associate

  • Chicago
View All Professionals

Capabilities 44 results

Practice Area

Antitrust/Competition

Practice Area

Class Actions & Group Litigation

Winston has developed a consistent record of success handling class action cases in state and federal courts. The practice is anchored by seasoned class action lawyers, many of whom have been recognized by Chambers USA and other ranking organizations as being top practitioners in their field. Our clients rely on us to steer them through class action matters by drawing on the firm’s significant experience in resolving complex litigation using creative and aggressive arguments, across a broad range of class, collective, coordinated, and mass actions, as well multidistrict litigation. We also have succeeded at trial in several class actions—a rare occurrence....Read more

Industry

Life Sciences

Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations....Read more

Experience 111 results

Experience

|

October 1, 2025

AA Mission Acquisition Corp. II - Initial Public Offering

Winston & Strawn LLP represented AA Mission Acquisition Corp. II, a blank check company, in the recent closing of its $100 million Initial Public Offering (IPO). The offering consisted of 10,000,000 units priced at $10.00 per unit, before deducting underwriting discounts and estimated offering expenses. The units began trading on the New York Stock Exchange (NYSE) under the ticker symbol “YCY.U” on October 1, 2025....Read more

Experience

|

July 30, 2025

Following an Astounding Summary Judgment Win, Winston Secures Three Favorable Class Settlements in US$52+B Broiler Chicken Litigation

Represent Norman W. Fries, Inc. d/b/a Claxton Poultry Farms in a series of 15+ antitrust class actions consolidated in the Northern District of Illinois and brought by plaintiffs who allege that Claxton and the nation’s other largest poultry producers conspired to fix the price of broiler chickens in a scheme from 2008 to 2016 that raised the price for broiler chickens by artificially reducing supply....Read more

Experience

|

July 24, 2025

Linkhome Holdings Inc. IPO

Winston & Strawn LLP represented Linkhome Holdings Inc., a leading AI-powered U.S. real estate platform, in connection with its upsized $6 million initial public offering. The offering consisted of 1,500,000 shares of common stock priced at $4.00 per share, and the shares are expected to begin trading on the Nasdaq Capital Market under the ticker “LHAI” on July 24, 2025....Read more
View All Experience

Insights & News 839 results

In the Media

|

November 21, 2025

|

2 Min Read

Eva Davis Shares Insights on Structuring Tariff-Impacted Deals with Mergers & Acquisitions

Winston & Strawn partner Eva Davis spoke with Mergers & Acquisitions about how it is possible to close deals despite uncertainty surrounding potential tariff impacts. She explained that in two deals that were close to signing in March, there was enough of a cushion in the sellers’ valuation expectations that when tariffs took effect on April 1, they agreed to reduce the purchase price and do an earnout to make up for the reduction that allowed the deals to close in April and May. She noted that in each transaction, the purchase price was based on an Ebitda multiple calculated over either a trailing or projected 12-month period....Read more

Investigations, Enforcement, & Compliance Alerts

|

November 18, 2025

|

3 Min Read

Hegseth Announces Overhaul of DoD Acquisition

On November 7, 2025, the U.S. Department of Defense announced a comprehensive overhaul of its procurement strategy named the “Acquisition Transformation Strategy” (ATS). The ATS envisions a wartime-oriented process that aims to prioritize rapid fielding to get equipment into the hands of warfighters, industrial-base expansion, and tighter coupling of requirements, resourcing, and acquisition execution. The accompanying directives signal a consequential restructuring of U.S. defense acquisition, requirements, and security cooperation processes as the Department aims to disestablish legacy joint requirements governance in favor of an integrated, budget-aligned model that is focused on speed, accountability, and mission outcomes. The new “Warfighting Acquisition System” will replace the existing “Joint Capabilities Integration and Development System,” creating both new opportunities and risks for federal contractors as they navigate shifting compliance expectations and material risk exposures in all aspects of the defense acquisitions process, including budget overruns, timely performance, and exportability of next-generation platforms. 

Capital Markets & Securities Law Watch

|

November 14, 2025

|

6 Min Read

Back in Business: What the SEC’s Post-Shutdown Guidance Means for Issuers and Underwriters

On November 13, 2025, following the end of the federal government shutdown, the Securities and Exchange Commission (SEC) issued guidance that offers much‑needed clarity to issuers, underwriters, and advisors navigating filings made during and immediately after the shutdown. With more than 900 registration statements filed during the shutdown, questions quickly mounted regarding automatic effectiveness, the treatment of missing information under Rule 430A, acceleration mechanics, and the status of filings already in the review pipeline. The staff (the Staff) of the SEC’s Division of Corporation Finance (the Division) addressed these topics directly through a series of Questions and Answers. This alert explains the guidance, describes the practical implications for capital markets and M&A participants, and recommends near‑term steps to adapt filing and transaction timelines.

View All Insights & News

Other Results 36 results

Site Content

What Is the Price Range in an IPO?

The price range is a proposed price per share range for the IPO within which investors can bid for shares and which is often printed on the cover page of a preliminary prospectus. The price range has a minimum price, known as the floor price, and a maximum price, known as the cap price....Read more

Site Content

What Is the BPCIA?

Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) to provide an abbreviated pathway for biosimilars to gain FDA approval through submission of an abbreviated Biologics License Application (aBLA)....Read more

Site Content

What Is Dilution?

Dilution refers to the reduction in an existing shareholder’s ownership percentage of a company when the company issues additional shares. Dilution in an IPO results from a disparity between the public offering price in an IPO and the effective cash cost to persons who acquired shares prior to the IPO. Dilution is disclosed in the registration statement in a dilution table....Read more
Logo
facebookinstagramlinkedintwitteryoutube

Copyright © 2025. Winston & Strawn LLP

AlumniCorporate Transparency Act Task ForceDEI Compliance Task ForceEqual Rights AmendmentLaw GlossaryThe Oval UpdateWinston MinutePrivacy PolicyCookie PolicyFraud & Scam AlertsNoticesSubscribeAttorney Advertising